Broad neutralization of SARS-related viruses by human monoclonal antibodies.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
07 08 2020
Historique:
received: 14 05 2020
accepted: 11 06 2020
pubmed: 17 6 2020
medline: 25 8 2020
entrez: 17 6 2020
Statut: ppublish

Résumé

Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines.

Identifiants

pubmed: 32540900
pii: science.abc7424
doi: 10.1126/science.abc7424
pmc: PMC7299279
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Viral 0
Broadly Neutralizing Antibodies 0
Epitopes 0
Receptors, Coronavirus 0
Receptors, Virus 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

731-736

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI132317
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI073148
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127521
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007288
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142777
Pays : United States

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8388-92
pubmed: 7667300
Nature. 2014 Mar 13;507(7491):201-6
pubmed: 24499818
Methods Enzymol. 2002;350:87-96
pubmed: 12073338
Cell Rep. 2019 Sep 24;28(13):3300-3308.e4
pubmed: 31553901
Sci Immunol. 2016 Dec 16;1(6):
pubmed: 28111638
PLoS Pathog. 2018 Aug 13;14(8):e1007236
pubmed: 30102747
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
J Virol. 2015 Feb;89(4):1954-64
pubmed: 25428871
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Nature. 2016 Mar 3;531(7592):114-117
pubmed: 26855426
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Adv Virus Res. 2019;105:93-116
pubmed: 31522710
mBio. 2015 Jun 30;6(4):e00801
pubmed: 26126854
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Science. 2009 Jul 17;325(5938):332-6
pubmed: 19498109
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Anna Z Wec (AZ)

Adimab LLC, Lebanon, NH 03766, USA.

Daniel Wrapp (D)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Andrew S Herbert (AS)

U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Daniel P Maurer (DP)

Adimab LLC, Lebanon, NH 03766, USA.

Denise Haslwanter (D)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

Mrunal Sakharkar (M)

Adimab LLC, Lebanon, NH 03766, USA.

Rohit K Jangra (RK)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

M Eugenia Dieterle (ME)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

Asparouh Lilov (A)

Adimab LLC, Lebanon, NH 03766, USA.

Deli Huang (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Longping V Tse (LV)

Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Nicole V Johnson (NV)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Ching-Lin Hsieh (CL)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Nianshuang Wang (N)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Juergen H Nett (JH)

Adimab LLC, Lebanon, NH 03766, USA.

Elizabeth Champney (E)

Adimab LLC, Lebanon, NH 03766, USA.

Irina Burnina (I)

Adimab LLC, Lebanon, NH 03766, USA.

Michael Brown (M)

Adimab LLC, Lebanon, NH 03766, USA.

Shu Lin (S)

Adimab LLC, Lebanon, NH 03766, USA.

Melanie Sinclair (M)

Adimab LLC, Lebanon, NH 03766, USA.

Carl Johnson (C)

Adimab LLC, Lebanon, NH 03766, USA.

Sarat Pudi (S)

Adimab LLC, Lebanon, NH 03766, USA.

Robert Bortz (R)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

Ariel S Wirchnianski (AS)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

Ethan Laudermilch (E)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

Catalina Florez (C)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

J Maximilian Fels (JM)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

Cecilia M O'Brien (CM)

U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Barney S Graham (BS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

David Nemazee (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Dennis R Burton (DR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA.

Ralph S Baric (RS)

Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

James E Voss (JE)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Kartik Chandran (K)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10462, USA.

John M Dye (JM)

U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Jason S McLellan (JS)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Laura M Walker (LM)

Adimab LLC, Lebanon, NH 03766, USA. laura.walker@adimab.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH